alexa
Reach Us +44-1647-403003
Recurrent Interstitial Lung Disease Induced By Various Therapies for Non-Small Cell Lung Cancer | OMICS International | Abstract
ISSN: 2165-7920

Journal of Clinical Case Reports
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Case Report

Recurrent Interstitial Lung Disease Induced By Various Therapies for Non-Small Cell Lung Cancer

Yu Saida1, Satoshi Watanabe2 *, Junko Baba3, Jun Koshio3, Rie Kondo3, Masaaki Okajima3, Satoru Miura3, Tetsuya Abe1, Hiroshi Tanaka1, Junta Tanaka3, Hiroshi Kagamu3, Hirohisa Yoshizawa2 and Ichiei Narita3
1Niigata Cancer Center Hospital, 951-8566 Niigata, Japan
2Bioscience Medical Research Center, Niigata University Medical and Dental Hospital, 951-8520 Niigata, Japan
3Department of Medicine (II), Niigata University Medical and Dental Hospital, 951-8520 Niigata, Japan
Corresponding Author : Satoshi Watanabe
Bioscience Medical Research Center
Niigata University Medical and Dental Hospital
951-8520 Niigata, Japan
Tel: +81- 25-227-2517
Fax: +81-25-227-2517
E-mail: [email protected]
Received November 06, 2014; Accepted December 24, 2014; Published December 31, 2014
Citation: Saida Y, Watanabe S, Baba J, Koshio J, Kondo R, et al. (2014) Recurrent Interstitial Lung Disease Induced By Various Therapies for Non-Small Cell Lung Cancer. J Clin Case Rep 4:471. doi:10.4172/2165-7920.1000471
Copyright: © 2014 Saida Y, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Erlotinib is a human epidermal growth factor receptor type 1 tyrosine kinase inhibitor which is used for non-small cell lung cancer treatment. Interstitial lung disease has been reported as an adverse event of erlotinib. We report the case of a 39-year-old man with erlotinib-induced interstitial lung disease in a non-small cell lung cancer patient. Although interstitial lung disease had improved by steroid therapy, palliative radiotherapy recalled the pneumonitis beyond the radiation fields. After the pneumonitis was well controlled, the patient was started on irinotecan, but the interstitial lung disease recurred shortly thereafter. We may have to abandon further cytotoxic therapies to avoid the recurrence of interstitial lung disease in patients who develop erlotinib-induced interstitial lung disease once.

Keywords

Top